HomeMRNA • NASDAQ
Moderna Inc
$125.00
After Hours:
$125.36
(0.29%)+0.36
Closed: May 3, 7:38:45 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$125.59
Day range
$122.01 - $126.40
Year range
$62.55 - $142.79
Market cap
47.86B USD
Avg Volume
3.44M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Mar 2024Y/Y change
Revenue
167.00M-91.03%
Operating expense
274.00M-10.16%
Net income
-1.18B-1,587.34%
Net profit margin
-703.59-16,694.10%
Earnings per share
-3.07-1,715.79%
EBITDA
-1.23B-327.08%
Effective tax rate
-0.86%
Total assets
Total liabilities
(USD)Mar 2024Y/Y change
Cash and short-term investments
8.52B-4.48%
Total assets
16.73B-30.66%
Total liabilities
3.91B-25.66%
Total equity
12.82B
Shares outstanding
382.00M
Price to book
3.74
Return on assets
-18.01%
Return on capital
-21.73%
Net change in cash
(USD)Mar 2024Y/Y change
Net income
-1.18B-1,587.34%
Cash from operations
-989.00M19.27%
Cash from investing
118.00M-94.13%
Cash from financing
14.00M102.58%
Net change in cash
-857.00M-451.23%
Free cash flow
-816.25M35.90%
About
Moderna, Inc. is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern". The company's only commercial product is the Moderna COVID-19 vaccine, marketed as Spikevax. The company has 45 treatment and vaccine candidates, of which 38 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, respiratory syncytial virus, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines. The company's pipeline also includes a cell therapy-based treatment: a relaxin fusion protein being developed to treat acute decompensated heart failure. Wikipedia
Founded
Sep 2010
Employees
5,600
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu